ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IVVD Invivyd Inc

0.4661
-0.0648 (-12.21%)
Last Updated: 19:06:42
Delayed by 15 minutes
Share Name Share Symbol Market Type
Invivyd Inc NASDAQ:IVVD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0648 -12.21% 0.4661 0.4632 0.4696 0.544999 0.4633 0.525 711,016 19:06:42

Invivyd to Participate in Upcoming Investor Conferences

05/09/2024 12:01pm

GlobeNewswire Inc.


Invivyd (NASDAQ:IVVD)
Historical Stock Chart


From Jul 2024 to Jan 2025

Click Here for more Invivyd Charts.

Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present at the following investor conferences:

Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside Chat Date: Friday, September 6, 2024Fireside Chat Time: 10:00 AM ETLocation: New York, NY

H.C. Wainwright 26th Annual Global Investment ConferenceFireside Chat Date: Monday, September 9, 2024Fireside Chat Time: 9:30 AM ETLocation: New York, NY

2024 Cantor Global Healthcare ConferenceFireside Chat Date: Wednesday, September 18, 2024Fireside Chat Time: 10:55 AM ETLocation: New York, NY

Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived for approximately 90 days following the events.

About InvivydInvivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Contacts:

Media Relations(781) 208-0160media@invivyd.com

Investor Relations(781) 208-0160investors@invivyd.com

1 Year Invivyd Chart

1 Year Invivyd Chart

1 Month Invivyd Chart

1 Month Invivyd Chart

Your Recent History

Delayed Upgrade Clock